Get the Stockscreener App
1.11
0.91%
0.01
After Hours:
1.13
0.02
+1.80%
Cognition Therapeutics Inc stock is traded at $1.11, with a volume of 1.00M.
It is up +0.91% in the last 24 hours and down -0.89% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.10
Open:
$1.15
24h Volume:
1.00M
Relative Volume:
1.21
Market Cap:
$97.98M
Revenue:
-
Net Income/Loss:
$-27.99M
P/E Ratio:
-2.3368
EPS:
-0.475
Net Cash Flow:
$-29.53M
1W Performance:
+0.91%
1M Performance:
-0.89%
6M Performance:
-11.90%
1Y Performance:
+141.67%
1-Day Range:
$1.09
$1.17
1-Week Range:
$1.03
$1.17
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.11 | 97.10M | 0 | -27.99M | -29.53M | -0.475 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia With Lewy Bodies - Neurology Live
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail
Cognition Therapeutics sets March 26 webcast on 2025 results - Stock Titan
Cognition presents data on dementia drug zervimesine at conference By Investing.com - Investing.com South Africa
CGTX PE Ratio & Valuation, Is CGTX Overvalued - Intellectia AI
Cognition presents data on dementia drug zervimesine at conference - Investing.com
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Bitget
Cognition Therapeutics Presents Promising Phase 2 Results of Zervimesine for Dementia with Lewy Bodies at AD/PD 2026 Conference - Quiver Quantitative
Cognition Therapeutics Presents Evidence of Zervimesine’s - GlobeNewswire
Dementia trial drug slowed neuropsychiatric decline 86% vs placebo - Stock Titan
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aug Intraday: Can Cognition Therapeutics Inc lead its sector in growthQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
MACD Signal: What is the dividend yield of Cognition Therapeutics IncDividend Hike & AI Based Trade Execution Alerts - baoquankhu1.vn
Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia
Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget
Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks
Cognition Therapeutics, Inc. Announces Advancement of Zervimesine Development for Dementia with Lewy Bodies Psychosis Treatment - Quiver Quantitative
Cognition Therapeutics advancing zervimesine (ct1812) for dementia with Lewy bodies (DLB) psychosis - marketscreener.com
Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes - TradingView
Cognition Therapeutics Advancing Zervimesine (Ct1812) For Dementia With Lewy Bodies (DLB) Psychosis - TradingView
Zervimesine push: Cognition Therapeutics (NASDAQ: CGTX) targets DLB psychosis - Stock Titan
DLB psychosis often untreated — zervimesine study targets hallucinations - Stock Titan
CGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
COGNITION THERAPEUTICS, INC. (CGTX) Stock, Price, News, Quotes, Forecast and Insights - MSN
Can Cognition Therapeutics Inc disrupt its industryQuarterly Profit Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Is Cognition Therapeutics Inc. stock a safe buy before earningsWeekly Trend Report & High Conviction Trade Alerts - mfd.ru
Whale Trades: Is Cognition Therapeutics Inc stock heavily shortedPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
CGTX (CGTX) CFO reports tax-withholding share disposition on RSU vesting - Stock Titan
Is Cognition Therapeutics Inc. stock overvalued by current metrics2025 Key Highlights & High Win Rate Trade Alerts - mfd.ru
Why Cognition Therapeutics Inc. stock is recommended by analysts2025 Market WrapUp & Reliable Volume Spike Alerts - mfd.ru
FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M - MarketBeat
Brookline Capital Management Predicts CGTX FY2025 Earnings - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management - Defense World
Cognition Therapeutics extends expanded access program for Zervimesine (CT1812) in dementia with Lewy bodies - marketscreener.com
Cognition Therapeutics rises as it extends access to rare brain disorder drug - TradingView
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics (NASDAQ:CGTX) Raised to "Strong-Buy" at Brookline Capital Management - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Shares Up 4.6% – Still a Buy? - Defense World
Analyst Calls: Is Cognition Therapeutics Inc. stock a safe buy before earnings2025 Top Gainers & Precise Entry and Exit Recommendations - mfd.ru
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug - Investing.com India
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug By Investing.com - Investing.com Canada
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial - TipRanks
Cognition Therapeutics Completes FDA Meeting for Zervimesine in DLB - TradingView
Cognition Therapeutics, Inc. Discusses Phase 2b Study Plans for Zervimesine in Dementia with Lewy Bodies During FDA Type C Meeting - Quiver Quantitative
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Street Watch: What is LCFYWs valuation compared to sectorTrade Risk Assessment & Stock Portfolio Risk Management - baoquankhu1.vn
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):